Clinical Trials Logo
  1. Home
  2. Colorectal Tumors
  3. NCT05136092

A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors

Colorectal Tumors Clinical Trial

Official title:
A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors

Clinical Trial Summary

This proposed study is designed to investigate the specific uptake of fructose by human colorectal tumors. In this study, subjects with colorectal cancer undergoing surgery will receive an oral sugar solution containing fructose or xylose prior to surgery. The tumor will then be resected, and a portion of the tissue will be used to measure the abundance of fructose and xylose. The study hypothesis is that the tumors will take up fructose sugar but not xylose sugar. A comparison of the sugar uptake between the tumor and normal tissues from the adjacent intestinal epithelium and smooth muscle and the liver will be conducted. This proposal will confirm that human colorectal cancer tumors can directly absorb dietary sugars, which has never been demonstrated.

Clinical Trial Description

This prospective pilot study is designed to investigate the uptake of dietary fructose and xylose by primary human colon tumors. In this study, the recruited patients with colorectal cancer will receive an oral sugar solution containing either Fructose sugar or Xylose sugar before surgery. The tumor will then be resected and a portion of the tumor, normal intestinal tissue, blood, urine, and liver will be used to quantify fructose and xylose. - Research question Can primary human tumors take up fructose or xylose? - A statement of the hypothesis The hypothesis is that fructose, but not xylose, can be directly absorbed and stored by primary human colon tumors. - Design Prospective, non-randomized, pilot, feasibility, single-center, open-label, phase 1, investigator-initiated study to evaluate the uptake of dietary fructose and xylose by primary human colon tumors with 12 subjects in 2 cohorts: Cohort 1: 6 subjects will consume a sugar solution containing fructose and Cohort 2: 6 subjects will consume a sugar solution containing xylose. Eligible subjects that are scheduled to undergo colorectal resection for cancer treatment will be invited to participate in the study in consecutive order from the practice of colorectal surgeons at the time of their preoperative clinic visit. First, Cohort 1 subjects will be enrolled followed by the Cohort 2 subjects. N=12 Subjects Cohort 1: Fructose sugar solution =6 Subjects Cohort 2: Xylose sugar solution=6 Subjects ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05136092
Study type Interventional
Source Weill Medical College of Cornell University
Contact Rohit Rasane
Phone 646-962-2789
Email rkr4004@med.cornell.edu
Status Recruiting
Phase N/A
Start date February 16, 2022
Completion date December 31, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT00704600 - Nelfinavir, a Phase I/Phase II Rectal Cancer Study Phase 1/Phase 2
Recruiting NCT05358249 - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Phase 1/Phase 2
Terminated NCT01545141 - Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer Phase 1/Phase 2
Withdrawn NCT01157039 - A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin Phase 2
Completed NCT03428958 - A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment Phase 1/Phase 2
Completed NCT01291420 - Dendritic Cell Vaccination for Patients With Solid Tumors Phase 1/Phase 2
Completed NCT00478634 - A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer Phase 1
Completed NCT05484687 - Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors N/A
Completed NCT01139138 - Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer Phase 1/Phase 2
Completed NCT01671592 - Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI) Phase 1
Completed NCT02399059 - Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution & Oncologic Outcome Phase 3
Active, not recruiting NCT03377361 - An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread Phase 1/Phase 2
Completed NCT01793207 - Peripheral Blood DNA Methylation Markers for the Early Detection of Colorectal Carcinoma in the Egyptian Population N/A
Completed NCT04166383 - VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) Phase 2
Completed NCT02347735 - Predictive Factors for Anastomotic Leakage After Colorectal Surgery
Active, not recruiting NCT01675128 - ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer Phase 1/Phase 2
Terminated NCT03050814 - Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 Phase 2